Novartis Sells U.S. Rights to Enablex for $400 Million

Novartis (NVS) agreed to sell the U.S. rights to bladder medicine Enablex for $400 million.

Ireland-based Warner Chilcott will take over the marketing, sales and manufacturing of the drug in the United States, Novartis said in a statement. The deal is expected to close by the end of October.

Sponsored Links
Novartis may also receive "milestone payments" of as much as $20 million.

In 2005, Novartis agreed to work with Procter & Gamble Pharmaceuticals to promote and develop the drug in the United States. Warner Chilcott purchased Procter & Gamble Pharmaceuticals in October 2009.
Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.